6533b834fe1ef96bd129e264
RESEARCH PRODUCT
HAV infection in chronic liver disease: a rationale for vaccination.
Piero Luigi AlmasioPietro Amorososubject
Pediatricsmedicine.medical_specialtyvirusesPopulationChronic liver diseaseVirusMedicineHumanseducationeducation.field_of_studyHepatitis A VaccinesGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryLiver DiseasesfungiPublic Health Environmental and Occupational Healthvirus diseasesbiochemical phenomena metabolism and nutritionHepatitis Abiology.organism_classificationmedicine.diseasedigestive system diseasesVaccinationInfectious DiseasesChronic diseaseImmunologyChronic DiseaseMolecular MedicineViral diseaseHepatovirusbusinessSystematic searchdescription
We report the conduct and results of a systematic search of the literature to assess whether exposure to HAV could induce a fatal deterioration of liver diseases. We assessed 30 studies and found evidence of progressive decrease of natural immunity against HAV in Italy. HAV vaccine seems as safe in chronic liver diseases than in general population. On the basis of the evidence we recommend that subjects with chronic liver disease should be vaccinated against HAV, especially if younger than 40 years.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2003-06-01 | Vaccine |